Novel Potential Therapeutic Targets in Autosomal Dominant Polycystic Kidney Disease from the Perspective of Cell Polarity and Fibrosis

被引:2
|
作者
Ahn, Yejin [1 ]
Park, Jong Hoon [1 ,2 ]
机构
[1] Sookmyung Womens Univ, Dept Biol Sci, Seoul 04310, South Korea
[2] Sookmyung Womens Univ, Res Inst Womens Hlth, Seoul 04310, South Korea
关键词
ADPKD; Kidney; Cell polarity; Fibrosis; Therapeutic target; DEACETYLASE; 6; ACTIVITY; PROTEIN-KINASE AMPK; E-CADHERIN; RENAL CYSTOGENESIS; CLINICAL-TRIAL; MTOR PATHWAY; CYST GROWTH; MOUSE MODEL; IN-VITRO; INHIBITION;
D O I
10.4062/biomolther.2023.207
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Autosomal dominant polycystic kidney disease (ADPKD), a congenital genetic disorder, is a notable contributor to the prevalence of chronic kidney disease worldwide. Despite the absence of a complete cure, ongoing research aims for early diagnosis and treatment. Although agents such as tolvaptan and mTOR inhibitors have been utilized, their effectiveness in managing the disease during its initial phase has certain limitations. This review aimed to explore new targets for the early diagnosis and treatment of ADPKD, considering ongoing developments. We particularly focus on cell polarity, which is a key factor that influences the process and pace of cyst formation. In addition, we aimed to identify agents or treatments that can prevent or impede the progression of renal fibrosis, ultimately slowing its trajectory toward end -stage renal disease. Recent advances in slowing ADPKD progression have been examined, and potential therapeutic approaches targeting multiple pathways have been introduced. This comprehensive review discusses innovative strategies to address the challenges of ADPKD and provides valuable insights into potential avenues for its prevention and treatment.
引用
收藏
页码:291 / 300
页数:10
相关论文
共 50 条
  • [31] Autosomal Dominant Polycystic Kidney Disease
    Srivastava, Ajay
    Patel, Neel
    AMERICAN FAMILY PHYSICIAN, 2014, 90 (05) : 303 - 307
  • [32] Autosomal Dominant Polycystic Kidney Disease
    Ekser, Burcin
    Rigotti, Paolo
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (01): : 71 - 71
  • [33] Therapeutic Potential of Ketogenic Interventions for Autosomal-Dominant Polycystic Kidney Disease: A Systematic Review
    Li, Donglai
    Dawson, Jessica
    Gunton, Jenny E.
    NUTRIENTS, 2025, 17 (01)
  • [34] Assessing the Therapeutic Potential of Readthrough of Nonsense Mutations in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Dillinger, Elizabeth K.
    Harris, Peter C.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 396 - 396
  • [35] Targeting TRPM3 as a potential therapeutic approach for autosomal dominant polycystic kidney disease
    Guel, Hueseyin
    Davies, Jamie A.
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [36] Autosomal dominant polycystic kidney disease: New pathophysiological and therapeutic aspects
    Wüthrich R.
    Fischereder M.
    Der Nephrologe, 2016, 11 (4): : 268 - 274
  • [37] Therapeutic Possibility of Ascofuranone for Autosomal Dominant Polycystic Kidney Disease - Response
    Jeong, Ji-Hak
    Magae, Junji
    Chang, Young-Chae
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (11) : 3101 - 3101
  • [39] Citrate in autosomal dominant polycystic kidney disease: biomarker or therapeutic agent?
    Rocha, Daniel Ribeiro
    Matos, Ana Cristina Carvalho
    Heilberg, Ita Pfeferman
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2025, 34 (02): : 138 - 142
  • [40] Renal Cell Carcinoma in Autosomal Dominant Polycystic Kidney Disease
    Nishimura, Hiroaki
    Ubara, Yoshifumi
    Nakamura, Michio
    Nakanishi, Shohei
    Sawa, Naoki
    Hoshino, Junichi
    Suwabe, Tatsuya
    Takemoto, Fumi
    Nakagawa, Masayuki
    Takaichi, Kenmei
    Tomikawa, Shinji
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 54 (01) : 165 - 168